Komori
Share Issuance and Disposal4579RaQualia Pharma Inc.Pharmaceuticals

Notice Regarding Completion of Payment for the Issuance of New Shares as Restricted Stock Compensation for Directors

Payment has been completed for 12,840 new shares issued as restricted stock compensation to 2 directors, as resolved on 25 March 2026.

Worth reading
29Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
12840
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares as restricted stock compensation

Who receives how much12,840Shares

12,840 common shares of the Company

2 directors of the Company, excluding directors who are Audit & Supervisory Committee members and outside directors; 12,840 shares

The lower thin line represents the existing number of shares to which these shares will be added.

¥795 per share
Total issue value

¥10,207,800

Categories and Number of Persons Covered
2 directors of the Company, excluding directors who are Audit & Supervisory Committee members and outside directors; 12,840 shares
Payment date
24 April 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares as restricted stock compensation
Number of shares to be issued or disposed of12,840 common shares of the Company
Issue price and disposal price¥795 per share
Total issue value¥10,207,800
Payment date24 April 2026
Intended allottee2 directors of the Company, excluding directors who are Audit & Supervisory Committee members and outside directors; 12,840 shares
Categories and Number of Persons Covered2 directors of the Company, excluding directors who are Audit & Supervisory Committee members and outside directors; 12,840 shares
Items this document does not state (21)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To issue the shares as restricted stock compensation for directors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Completion of Payment for the Issuance of New Shares as Restricted Stock Compensation for Directors | RaQualia Pharma Inc. (4579) timely disclosure | Komori